Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand · Tablet · Updated Nov 11, 2026

Foundayo 9 mg tablet price what pharmacies pay, and what you should

Pharmacies pay$627.49for 30 tablets · $20.92 per tablet
Fair cash price$732.11cost + 15% + $10.50 fee
+0.3% in 4 weeksLast change Oct 21, 2026: pharmacies' invoice prices changed (survey)

Is my price fair?

Check the price you were quoted

Type what the pharmacy asked for foundayo 9 mg tablet and see the markup over what they pay.

How many?
$
Pharmacies payNADAC this week$627.49
Online cost-pluscost + 15% + fees$731.61
Fair cash pricecost + 15% + $10.50 fee$732.11
Your quotetype it above-
Pharmacies pay about $627.49 for 30 tablets. A fair cash price is around $732.11. Type your quote to see your markup.

A benchmark from public data, not a price offer or medical advice. Prices vary by pharmacy, insurance and discount programs.

Foundayo 9 mg price history

What pharmacies pay for 30 tablets, weekly
$588.96$614.02$639.08$664.14Oct
What pharmacies paid for 30 tablets of foundayo 9 mg tablet over 52 weeks: from $625.61 on Sep 23, 2026 to $627.49 on Nov 11, 2026.
Now
$627.49
52-week low
$625.61
52-week high
$627.49
A year ago
-

Why the price changed

EffectiveBeforeAfterChangeReason
Oct 21, 2026$20.85$20.92+0.3%pharmacies' invoice prices changed (survey)

Prices per tablet. Reasons are the ones the national survey gives: a survey rate change comes from pharmacies' own invoices; a published price change follows the maker's list price.

What did you pay for foundayo 9 mg tablet? Share it.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recallsNone on record

Every manufacturer and package code

1 company sell foundayo 9 mg tablet under 2 package codes (NDCs). Pharmacies pay the same per tablet whichever maker they buy from - the national average is set for the generic as a group.

MakerPack sizesPackage codesPer unit
Eli Lilly and Company30 tablets0002-4803-31 $20.92
All 2 package codes

1 older package code is still priced but no longer in the current FDA listing.

A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.

Questions to ask your pharmacist

  1. "What is your cash price, without insurance?" For low-cost generics it can be less than a copay.
  2. "Is a 90-day supply cheaper per tablet?" Dispensing fees are charged per fill, so fewer fills often cost less.
  3. "Do you match other pharmacies or accept discount cards?" Many do, if you ask.

These are questions, not advice. Never change how you take a medicine without talking to your prescriber or pharmacist.

Other foundayo strengths and forms

Strength and formPer unitPharmacies pay4 weeks52 weeks
0.8 mg tablet Brand$20.92$627.48 / 30 tablets+0.1%
2.5 mg tablet Brand$20.89$626.78 / 30 tablets+0.3%
5.5 mg tablet Brand$20.88$626.34 / 30 tablets+0.3%
14.5 mg tablet Brand$20.83$624.85 / 30 tablets
17.2 mg tablet Brand$21.08$632.28 / 30 tablets

Official label & what changed

Last changedAugust 13, 2026
Version10 of 2
EffectiveJul 29, 2026
Read the label

These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO.FOUNDAYO (orforglipron) tablets, for oral useInitial U.S. Approval: 2026

This drug has a boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS

In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology (13.1)]. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].

FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of FOUNDAYO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with FOUNDAYO [see Contraindications (4), Warnings and Precautions (5.1)].

WARNING: RISK OF THYROID C-CELL TUMORS

See full prescribing information for complete boxed warning.

In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents (13.1). While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined (5.1, 13.1).

FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4, 5.1).

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Questions about foundayo 9 mg tablet

How much does foundayo 9 mg tablet cost without insurance?

Pharmacies pay about $627.49 for 30 tablets ($20.92 per tablet) as of November 11, 2026. A fair cash price is about $732.11: that cost plus a 15% margin and a $10.50 dispensing fee. Online cost-plus pharmacies charge around $731.61 including shipping.

Is my price for foundayo 9 mg tablet fair?

Compare it with the fair cash price of $732.11 for 30 tablets. Up to about $915.14 is fair; above $1,464.22 is high, and worth asking the pharmacy for its cash price or trying another pharmacy. Check your quote.

Is foundayo 9 mg tablet getting more expensive?

Over the last four weeks the price pharmacies pay held steady. See the 52-week chart.

Who makes foundayo 9 mg tablet?

1 company: Eli Lilly and Company. See every package code.

Is foundayo in shortage?

No shortage is reported right now. We check every day.

Has foundayo been recalled?

No recalls are on record.

What does "pharmacies pay" mean?

It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.

Talk about foundayo 9 mg tablet

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.